<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01965223</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 13.01</org_study_id>
    <secondary_id>TROG 13.01</secondary_id>
    <secondary_id>13001</secondary_id>
    <secondary_id>1111-1136-6607</secondary_id>
    <nct_id>NCT01965223</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)</brief_title>
  <acronym>SAFRON II</acronym>
  <official_title>Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australasian Lung Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans-Tasman Radiation Oncology Group (TROG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety (defined as number of participants
      experiencing ≥ 5% toxicity at 12 months post treatment) of stereotactic ablative fractionated
      radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotactic Ablative Body Radiotherapy (SABR) is an exciting novel radiotherapy technique
      that is delivered over very few sessions. In the case of limited pulmonary 'oligometastases',
      SABR can result in long-term survival. It is non-invasive and associated with high rates of
      tumour control and relatively low toxicity. Additionally, the large doses of precision
      radiotherapy involved may evoke a strong immune response to recognise and attack any
      remaining tumour cells. In the future, SABR may be an attractive alternative to invasive
      surgery. There are two SABR techniques emerging in Australia; fractionated and single
      fraction treatments. We aim to conduct the first clinical trial of SABR in patients with
      limited pulmonary metastases testing fractionated versus single fraction treatments.

      The primary aim of this study is to evaluate the toxicity, Quality of Life, clinical efficacy
      and cost effectiveness of single fraction SABR compared to multi-fraction SABR in patients
      with oligometastases to the lung.

      The secondary aim of this study is to assess the immune response evoked by both fractionated
      and single fraction SABR and its prognostic implications for patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 4, 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome is safety, defined as number of participants experiencing less than or equal to 5% toxicity at 12 months post treatment (toxicity as measured by CTCAE V4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>To compare quality of life outcomes between techniques assessed using EQ-5DL and MDASI-LC questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local failure</measure>
    <time_frame>24 months</time_frame>
    <description>Local progression free survival assesed by CT scan and clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival assesed by clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant failure</measure>
    <time_frame>24 months</time_frame>
    <description>Time to distant failure assessed by CT scan and clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resources use and costs associated with treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Resources use and costs associated with treatment assessed by EQ5DL and accessing Medicare data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Disease free survival will be measured from the date of randomisation to the date of a local recurrence, regional or distant metastasis, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune response</measure>
    <time_frame>3 months</time_frame>
    <description>To explore immune system responses to single fraction and multi-fraction SABR.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Cancer</condition>
  <condition>Metastases to the Lung</condition>
  <arm_group>
    <arm_group_label>Multi-fraction SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single fraction SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: 28Gy delivered in 1 fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Multi-fraction SABR</intervention_name>
    <description>Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.</description>
    <arm_group_label>Multi-fraction SABR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Single Fraction SABR</intervention_name>
    <description>Single fraction SABR; 28Gy delivered in 1 fraction</description>
    <arm_group_label>Single fraction SABR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A maximum of three metastases to the lung from any non-haematological malignancy

          2. Tumour diameter ≤5cm

          3. Targets are located away from central structures (defined as 2cm beyond bifurcation of
             lobar bronchi and central airways). Targets in proximity to chest wall and mediastinum
             that meet these inclusion criteria are eligible.

          4. Patients must be medically inoperable, technically high risk or have declined surgery.

        Exclusion Criteria:

          1. Previous high-dose thoracic radiotherapy.

          2. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently
             with treatment. Hormonal manipulation agents are not excluded (e.g. aromatase
             inhibitors, selective oestrogen receptor modulators, and gonadotrophin releasing
             hormone receptor modulators)

          3. Targeted agents (such as sunitinib and tarceva) within 7 days of commencement of
             treatment, or concurrently with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shankar Siva</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Sydney Cancer Centre (RNS)</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambelltown Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 13, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2013</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligometastatic</keyword>
  <keyword>Neoplasia</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Stereotactic Ablative Body Radiotherapy</keyword>
  <keyword>SABR</keyword>
  <keyword>Metastases to the Lung</keyword>
  <keyword>Non Haematological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

